Mylan N.V. (NASDAQ:MYL) updated its FY17 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of $4.45-4.70 for the period, compared to the Thomson Reuters consensus estimate of $4.59. The company issued revenue guidance of $11.75-12.5 billion, compared to the consensus revenue estimate of $12.07 billion.Mylan N.V. also updated its FY18 guidance to $5.40 EPS.
MYL has been the subject of a number of analyst reports. Zacks Investment Research cut Mylan N.V. from a buy rating to a hold rating in a research note on Wednesday, November 8th. Royal Bank Of Canada upped their price objective on Mylan N.V. from $32.00 to $37.00 and gave the stock a sector perform rating in a research note on Tuesday, November 7th. Cantor Fitzgerald set a $34.00 price objective on Mylan N.V. and gave the stock a hold rating in a research note on Tuesday, October 31st. BidaskClub upgraded Mylan N.V. from a hold rating to a buy rating in a research note on Friday, October 27th. Finally, Mizuho reaffirmed a buy rating and set a $37.00 target price on shares of Mylan N.V. in a research report on Tuesday, October 24th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and thirteen have issued a buy rating to the stock. The company has an average rating of Buy and an average price target of $41.49.
Mylan N.V. (NASDAQ MYL) traded up $0.28 during trading on Wednesday, reaching $37.85. The company had a trading volume of 3,732,800 shares, compared to its average volume of 5,986,239. The firm has a market capitalization of $20,300.00, a price-to-earnings ratio of 7.99, a price-to-earnings-growth ratio of 2.06 and a beta of 1.38. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.95 and a current ratio of 1.46. Mylan N.V. has a 12-month low of $29.39 and a 12-month high of $45.87.
Mylan N.V. (NASDAQ:MYL) last issued its quarterly earnings results on Monday, November 6th. The company reported $1.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.10). The business had revenue of $2.99 billion for the quarter, compared to analysts’ expectations of $3.09 billion. Mylan N.V. had a return on equity of 20.63% and a net margin of 7.28%. The business’s revenue for the quarter was down 2.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.38 EPS. sell-side analysts anticipate that Mylan N.V. will post 4.56 earnings per share for the current fiscal year.
About Mylan N.V.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.